Interferon gamma-1b in the treatment of idiopathic pulmonary fibrosis

被引:11
作者
Pacanowski, MA [1 ]
Amsden, GW [1 ]
机构
[1] Bassett Healthcare, Clin Pharmacol Res Ctr, Dept Pharmaceut Care Serv, Clin Pharmacol Sect, Cooperstown, NY 13326 USA
关键词
cryptogenic fibrosing alveolitis; idiopathic pulmonary fibrosis; interferon;
D O I
10.1345/aph.1E672
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To examine the clinical aspects of idiopathic pulmonary fibrosis (IPF) and the efficacy and safety of interferon gamma-1b (IFN gamma-1b) in its treatment. DATA SOURCES: Epidemiologic, preclinical, and clinical studies published in the English language were identified by a MEDLINE search (1966-January 2005) using the search terms idiopathic pulmonary fibrosis, cryptogenic fibrosing alveolitis, and interferon. Additional citations were identified from the reference lists of related publications. STUDY SELECTION AND DATA EXTRACTION: Selected preclinical studies describing the pathophysiologic basis for IFN gamma-1b therapy and all clinical studies were included. Additional trials describing other treatment modalities and the determinants of response to therapy in patients with IPF were also reviewed. DATA SYNTHESIS: IFN gamma-1b targets the fibrotic rather than inflammatory processes of IPF The efficacy of IFN gamma-1b in patients with IPF is inconsistent with regard to changes in pulmonary function and mortality, although a modest survival benefit was observed in the largest clinical trial. Adverse events related to IFN gamma-1b are frequent although transient. Several cases of respiratory failure occurring subsequent to the administration of IFN gamma-1b are documented. CONCLUSIONS: To date, although trials suggest that earlier-stage IPF may be responsive to IFN gamma-1b, study results overall are inconsistent; further investigation is needed.
引用
收藏
页码:1678 / 1686
页数:9
相关论文
共 60 条
[1]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00
[2]  
ANTONIOU KM, 2003, 99 INT C AM THOR SOC
[3]   The effect of interferon alone vs interferon plus corticosteroids in patients with idiopathic pulmonary fibrosis [J].
Bell, AM ;
Nathan, SD ;
Shorr, AF ;
Barnett, SD ;
Helman, DL .
CHEST, 2003, 124 (04) :117S-117S
[4]  
BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118
[5]   Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis [J].
Bjoraker, JA ;
Ryu, JH ;
Edwin, MK ;
Myers, JL ;
Tazelaar, HD ;
Schroeder, DR ;
Offord, KP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (01) :199-203
[6]   EFFECTS OF INTERFERON-GAMMA ON EXPRESSION OF CELL-SURFACE RECEPTORS FOR COLLAGEN AND DEPOSITION OF NEWLY SYNTHESIZED COLLAGEN BY CULTURED HUMAN-LUNG FIBROBLASTS [J].
CLARK, JG ;
DEDON, TF ;
WAYNER, EA ;
CARTER, WG .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (05) :1505-1511
[7]   Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].
Collard, HR ;
King, TE ;
Bartelson, BB ;
Vourlekis, JS ;
Schwarz, MI ;
Brown, KK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542
[8]  
Crestani B, 2004, AM J RESP CRIT CARE, V169, P544
[9]   A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis [J].
Daniil, ZD ;
Gilchrist, FC ;
Nicholson, AG ;
Hansell, DM ;
Harris, J ;
Colby, TV ;
du Bois, RM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (03) :899-905
[10]   Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis - A randomized prospective study [J].
Douglas, WW ;
Ryu, JH ;
Swensen, SJ ;
Offord, KP ;
Schroeder, DR ;
Caron, GM ;
DeRemee, RA ;
Fisk, DM ;
Krowka, MJ ;
Patel, AM ;
Schwartz, OA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (01) :220-225